Irish heart drug company Amarin has secured approval from Canadian authorities to sell its one drug in that market. The company estimates that the market in the United States alone is more than six million patients. The drug will be sold in Canada through HLS Therapeutics, which negotiated exclusive rights with Amarin. HLS currently expects Canadian sales of Vascepa to reach between 150 and 250 million Canadian dollars a year. In the wake of the US approval, Amarin raised its forecast for 2020 sales to somewhere between $650 million and $700 million.

Source: The Irish Times January 02, 2020 19:26 UTC